AnaptysBio (ANAB) Earning Somewhat Favorable News Coverage, Report Shows

Press coverage about AnaptysBio (NASDAQ:ANAB) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.0672031921792 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media headlines that may have effected Accern Sentiment’s rankings:

A number of research firms have commented on ANAB. Stifel Nicolaus restated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a report on Tuesday, September 12th. Royal Bank Of Canada raised their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research report on Wednesday, September 13th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC initiated coverage on shares of AnaptysBio in a research report on Thursday, November 9th. They issued a “buy” rating and a $101.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $81.00.

Shares of AnaptysBio (ANAB) opened at $71.23 on Tuesday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 1 year low of $15.17 and a 1 year high of $74.00.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. research analysts expect that AnaptysBio will post -1.72 earnings per share for the current fiscal year.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

ILLEGAL ACTIVITY NOTICE: “AnaptysBio (ANAB) Earning Somewhat Favorable News Coverage, Report Shows” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply